GPHL delivers medicine overseas to help fight COVID-19

2020-04-03 11:27:40 GPHL GPHL

On March 23rd, 300,000 Chloroquine Phosphate Tablets produced by GPHL’s subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. (Guanghua) arrived at Soekarno-Hatta International Airport. This is the first batch of Guanghua’s medicine to be exported for the fight against COVID-19.

Chloroquine Phosphate Tablets produced by GPHL’s subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd.

Chloroquine Phosphate Tablets have been included into the sixth and seventh versions of guidelines for treating COVID-19 patients. Guanghua not only maintains a stable supply of this drug in the domestic market, but is also expanding supply worldwide. So far Guanghua has reached 18 countries through its cooperation with embassies, foundations and distributors.

In addition to the Chloroquine Phosphate Tablets, GPHL has received many overseas orders for Banlangen Granules, Antiviral Oral Liquid, masks and protective clothing.

GPHL’s subsidiary Guangzhou Baiyun Mountain and Hutchison Whampoa Ltd. manufactures Banlangen Granules.

In the middle of March, GPHL’s subsidiary Guangzhou Baiyun Mountain and Hutchison Whampoa Ltd. (BMHW) delivered 10,000 packs of Banlangen to the US by air as this kind of Chinese patent medicine was already out of stock across many regions in the country.

BMHW is also producing an overseas version of Banlangen specifically for export. The first 500 boxes of Banlangen are now ready to ship to the US and other regions.

GPHL chairman Li Chuyuan: A medical solution with Chinese characteristics combating the COVID-19 pandemic

More than a month ago, GPHL chairman Li Chuyuan tried every means possible to purchase 215,000 Chloroquine Phosphate Tablets from international sources. Now, the Chloroquine Phosphate Tablets produced by GPHL can not only satisfy domestic demand, but are also being exported to other areas affected by COVID-19.

GPHL chairman Li Chuyuan (Photo: Nanfang Plus)

Li said, “Chinese medicine continues to play an important role in China’s fight against COVID-19, and the global market has also developed a new understanding of Chinese medicine. This brings an unprecedented opportunity for China’s pharmaceutical industry.”

In order to respond to market demand and deal with risk, GPHL has made improvements across the board, including its manufacturing technology, supply chain and business model. For example, the ‘Suikang’ (穗康) mini-program jointly developed by GPHL and Tencent not only allows users to order masks online but is also able to analyse information about supply, mask purchases and consumer feedback.

“This reveals the positive role the internet and big data play in preventing and controlling the outbreak. In the future, we will further invest in this field, and accelerate the development of our intelligent and data-driven pharmaceutical business,” Li pointed out.

Staff members of Wanglaoji manufacture Keganliyan oral liquid.

According to the latest data from the State Council Information Office, clinical observation showed that the total effective rate of TCM treatment reached over 90%. TCM has proven effective in relieving symptoms, preventing mild and common cases from developing into severe cases, improving the recovery and reducing fatality rates, and boosting the patients’ rehabilitation process. Chinese medicine are a highlight of China’s ‘solution’ for combating the COVID-19 pandemic all over the world.

Li believes that this provides a good opportunity for Chinese medicine to expand their global market.

This year, GPHL’s international headquarters in Macao will work with organizations from Japan, South Korea and other countries to modernize development of Chinese medicine, to enable it meet modern international standards, and make it more accessible to the general public.

Meanwhile, GPHL has found new sources of growth in its response to coronavirus, such as resuming the production and export of Chloroquine Phosphate, and the well-received Flu Prevention Herbal Tea jointly developed by GPHL and Guangdong Hospital of Traditional Chinese Medicine.

Staff members of GPHL manufacture protective supplies.

GPHL’s two newly built facilities, the Baiyunshan Yihu Health Technology Co., Ltd. and the Baiyunshan Jingxiutang Pharmaceutical Co., Ltd. have the capacity to produce masks and protective equipment. These supplies can be sold to both domestic and foreign markets.

In addition, GPHL is exploring how to integrate Chinese medicine with apparel, food and drink, transportation and living environment in order to create innovative, fashionable and practical TCM products.

Authors: Michelle, Monica

Editor: Simon, Olivia